Filippo de Braud
Impact in
- Oncology top 0.02%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Hepatology top 0.2%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 487
- Colorectal Cancer Treatments and Studies 136
- Lung Cancer Research Studies 94
- Cancer Immunotherapy and Biomarkers 90
-
- Lung Cancer Treatments and Mutations 123
- Renal cell carcinoma treatment 64
- Gastric Cancer Management and Outcomes 64
- Co-authors
- Arié Figer (9 shared papers)Jim Cassidy (6 shared papers)C. Boni (6 shared papers)Eric Van Cutsem (13 shared papers)H. Cortés-Funes (3 shared papers)M. Homerin (3 shared papers)Filippo Pietrantonio (93 shared papers)P. Koralewski (4 shared papers)
- Journals
- Journal of Clinical Oncology (153 papers)Annals of Oncology (111 papers)Critical Reviews in Oncology/Hematology (29 papers)European Journal of Cancer (22 papers)Journal of Thoracic Oncology (21 papers)
- Partner nations
- ItalyUnited StatesFrance
In The Last Decade
Filippo de Braud
728 papers receiving 26.2k citations
Filippo de Braud's Hit Papers
Peers
Comparison fields: 5 of 162
- Oncology 17.9k
- Hepatology 2.5k
- Pulmonary and Respiratory Medicine 8.8k
- Cancer Research 3.7k
- Pathology and Forensic Medicine 3.3k
Countries citing papers authored by Filippo de Braud
This map shows the geographic impact of Filippo de Braud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filippo de Braud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filippo de Braud more than expected).
Fields of papers citing papers by Filippo de Braud
This network shows the impact of papers produced by Filippo de Braud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filippo de Braud. The network helps show where Filippo de Braud may publish in the future.
Co-authors
The 25 scholars most cited alongside Filippo de Braud, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 754 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer Hit paper breakdown → | 2000 | 3040 |
| 2 | Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 1245 |
| 3 | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Hit paper breakdown → | 2011 | 612 |
| 4 | Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer Hit paper breakdown → | 2011 | 533 |
| 5 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial Hit paper breakdown → | 2016 | 511 |
| 6 | CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer Hit paper breakdown → | 2018 | 471 |
| 7 | 2004 | 418 | |
| 8 | 2002 | 390 | |
| 9 | Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis Hit paper breakdown → | 2015 | 350 |
| 10 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the Hit paper breakdown → | 2020 | 335 |
| 11 | Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial Hit paper breakdown → | 2020 | 314 |
| 12 | 2010 | 308 | |
| 13 | 2009 | 308 | |
| 14 | 2016 | 268 | |
| 15 | 2018 | 265 | |
| 16 | 2018 | 233 | |
| 17 | 1998 | 233 | |
| 18 | 2005 | 224 | |
| 19 | 2019 | 218 | |
| 20 | 2011 | 217 |
About Filippo de Braud
Filippo de Braud is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Surgery, having authored 754 papers that have together received 26.7k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (136 papers), Lung Cancer Treatments and Mutations (123 papers), Lung Cancer Research Studies (94 papers), Cancer Genomics and Diagnostics (92 papers), Cancer Immunotherapy and Biomarkers (90 papers), Neuroendocrine Tumor Research Advances (73 papers), Renal cell carcinoma treatment (64 papers) and Gastric Cancer Management and Outcomes (64 papers). The work is most often cited by research in Oncology (17.9k citations), Hepatology (2.5k citations), Pulmonary and Respiratory Medicine (8.8k citations), Cancer Research (3.7k citations) and Pathology and Forensic Medicine (3.3k citations). Filippo de Braud has collaborated with scholars based in Italy, United States and France. Frequent co-authors include Arié Figer, Jim Cassidy, C. Boni, Eric Van Cutsem, H. Cortés-Funes, M. Homerin, Filippo Pietrantonio, P. Koralewski, Igor Bondarenko and Carsten Bokemeyer. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Critical Reviews in Oncology/Hematology, European Journal of Cancer and Journal of Thoracic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.